Results 81 to 90 of about 5,855 (210)
ABSTRACT Phytocannabinoids are bioactive metabolites derived from the Cannabis sativa plant. They have garnered attention due to their recreational uses and therapeutic potential. Although various analytical strategies have been employed for their analysis, mass spectrometry (MS) coupled to chromatographic separation is superior due to its sensitivity ...
Radwa Mahmoud +2 more
wiley +1 more source
Aim Comorbid anxiety disorders and their symptoms are common in schizophrenia and may occur before a relapse. The aim of this post hoc analysis is to investigate the efficacy of lurasidone on comorbid anxiety symptoms in patients with schizophrenia ...
Takahiro Nemoto +2 more
doaj +1 more source
Abstract Background Non‐motor symptoms (NMS), specifically anxiety and depression are major drivers of disability in Parkinson's disease (PD). Prevalence estimates remain inconsistent because of differences in population samples, diagnostic criteria, and symptom overlap, contributing to underdiagnosis and undertreatment.
Marshall Schmidt +4 more
wiley +1 more source
New clinical reports have recently been published on tofisopam—an anxiolytic drug currently registered as a benzodiazepine—after a long break in this research area.
Andrzej Kokoszka
doaj +1 more source
Use of anxiolytics and hypnotics - a pilot study
Introduction: Benzodiazepine anxiolytics and hypnotics are often used in therapy. Aim: To study the use of anxiolytics and hypnotics among pharmacy clients in the town of Plovdiv.Materials and methods: In 2005 a questionnaire study was carried out on the
Krasteva, E.; Medical University of Plovdiv +2 more
core +1 more source
Abstract Background Parkinson's disease (PD) is frequently accompanied by neuropsychiatric symptoms (NPS), including cognitive impairment, which often emerge early and co‐occur. Their long‐term evolution remains incompletely characterized, particularly in biomarker‐positive cohorts.
Izabelle Schoen +10 more
wiley +1 more source
Drug Interactions of Psychiatric and COVID-19 Medications
Introduction: Coronavirus disease 2019 (COVID-19) has become a pandemic with 1771514 cases identified in the world and 70029 cases in Iran until April 12, 2020. The co-prescription of psychotropics with COVID-19 medication is not uncommon.
Niayesh Mohebbi +4 more
doaj
Chronic use of hypnotics and anxiolytics
On request of the Chief-Inspectorate for Mental Health in the Netherlands an overview was made on the research in the Netherlands about the use of psychotropic compounds, viz.
Wieringa NF +7 more
core
ABSTRACT Opioid use disorder (OUD) remains a major global health challenge, and currently approved treatments (methadone, buprenorphine, and naltrexone) are all opioid receptor‐targeting drugs with limitations in access, adherence, stigma, and use in polysubstance use disorders. Because the dopamine D3 receptor (D3R) is enriched in limbic brain regions
Chia‐Kuei Wu +15 more
wiley +1 more source
Protocol for a systematic review and meta-analysis on the comparative effectiveness of propranolol and non-benzodiazepine anxiolytics for acute anxiety in non-psychiatric settings .(CRD420251039479)
Owais Nawaz Khan +3 more
core +1 more source

